The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives
Open accessAbstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly NAFLD, is the most prevalent chronic liver disease worldwide. Strongly linked to obesity, type 2 diabetes, and metabolic syndrome, MASLD poses a growing health burden. Despite its high prevalence and risk of progression, no pharmacological treatment is currently approved. This narrative review provides an overview of emerging pharmacological treatments under clinical investigation, with a particular focus on agents recently evaluated in randomized clinical trials. A systematic search of the ClinicalTrials.gov database through to April 2025 was conducted to identify relevant studies. Investigational drugs were categorized by their molecular mechanisms, and data on efficacy, safety, and clinical development phases were summarized. The most extensively studied drug classes include GLP-1 receptor agonists, PPAR agonists, and FXR agonists, as well as inhibitors of ACC and DGAT. These therapies have shown promising effects on hepatic steatosis, liver enzyme levels, and metabolic markers and may be introduced into clinical practice in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781 · cited 3×
“Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is the most common chronic liver disease worldwide, with an estimated prevalence affecting approximately 25–30% of the global population [1].”
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239 · cited 1×
“Most guidelines recommend a hypocaloric diet with a daily energy deficit of 500–1000 kcal, targeting gradual, sustainable weight loss [22,23].”
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 4×
“The PIVENS trial demonstrated significant improvement in steatohepatitis but not fibrosis among non-diabetic adults with biopsy-proven NASH [38].”
InfluentialThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119 · cited 1×
“This is best captured by the “multiple-hit” theory, which posits that liver steatosis and its progression to steatohepatitis, and fibrosis result from the cumulative, and often simultaneous, impact of several pathogenic factors (Figure 1) [8,9].”
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667 · cited 5×
“RCTs, including PIVENS, have shown histological improvements in steatosis, lobular inflammation, and hepatocellular ballooning in patients with MASH, especially those with T2DM [13,15,38–40].”
InfluentialEvolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548 · cited 1×
“This is best captured by the “multiple-hit” theory, which posits that liver steatosis and its progression to steatohepatitis, and fibrosis result from the cumulative, and often simultaneous, impact of several pathogenic factors (Figure 1) [8,9].”
Assessing mitochondrial dysfunction in cells
Brand, M. D., & Nicholls, D. G. (2011) · Biochemical Journal · doi:10.1042/bj20110162 · Cited by 2,405 · cited 1×
“These effects can contribute to decreased lipid accumulation and improved metabolic homeostasis [127,128].”
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 1×
“…acid (OCA), the most extensively studied FXR agonist, was evaluated in the FLINT trial (NCT01265498), where non-cirrhotic NASH patients receiving 25 mg daily for 72 weeks experienced notable improvements in liver histology, including reductions in steatosis, inflammation, and fibrosis [65–68].”
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“In the NCT02970942 trial, patients with biopsy-proven NASH and fibrosis stages F1–F3 received daily subcutaneous injections for 72 weeks [74].”
Cited by
Wang, L., Wang, Q., Xiong, Y., Shi, W. F., & Xiao, Q. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s540103 · Cited by 46
“21 The diagnostic workflow of MASLD integrates multiple approaches: 22,23 (1) Liver biopsyremains the gold standard for evaluating steatosis grade (SAF score), lobular inflammation, and fibrosis stage (NASH CRN scoring); (2) Non-invasive scores, particularly the FIB-4 index (incorporating age, ALT,…”
Caturano, A., Erul, E., Nilo, R., Nilo, D., Russo, V., Rinaldi, L., Acierno, C., Akkuş, E., Koudelková, K., Cerini, F., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70132 · Cited by 40
“1,72 While promising, these agents are primarily preventive rather than curative in HCC, and their protective effects must be confirmed in large MASLD-focused trials.”
Metabolic dysfunction‑associated steatotic liver disease: Pathogenesis, model and treatment (Review)
Ma, Q., Liu, K., Chang, C., Wang, L., Shen, Z.-Y., Li, J., Adu, M., Lin, Q., Huang, H., Wu, X., et al. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5668 · Cited by 23
Jamalinia, M., Saeian, S., Nikkhoo, N., Nazerian, A., & Lankarani, K. B. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.131 · Cited by 19
Ma, J., Xie, N., Wang, Z., Liang, X., Han, Y., Zhao, Q., Wang, M., Lu, H., Kou, W., Alazawi, W., et al. (2026) · Advanced Science · doi:10.1002/advs.202519109 · Cited by 14
Metadata
- Authors
- Drygalski, K.
- Affiliations
- Gdańsk Medical University (PL)
- Corresponding author
- Drygalski, Krzysztof
- ORCID
- Drygalski, Krzysztof
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2025-07-07
- Volume
- 26
- Issue
- 13
- Pages
- 6518
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC12249978
- OpenAlex
- W4412088572
- Cited by
- 39
- References
- 141
- Citations by year
- 2026: 34 · 2025: 5
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Servier
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- non-alcoholic fatty liver disease, pharmacotherapy, GLP-1 receptor agonists, PPAR agonists, FXR agonists, acetyl-CoA carboxylase inhibitors, hepatic steatosis, drug development, obesity, type 2 diabetes, metabolic syndrome
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. https://app.cochat.ai/papers/10.3390/ijms26136518
- The paper
- Drygalski, K. (2025). Pharmacological Treatment of MASLD: Contemporary Treatment and Future Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26136518
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


